| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $7,688,808 | 15 | 100 |
| Beckman Daniella | Chief Financial Officer | 0 | $0 | 1 | $126,531 | $-126,531 |
| Newcomb Jessica | Principal Accounting Officer | 0 | $0 | 1 | $198,613 | $-198,613 |
| Weber Barbara | Director, Executive Chair | 0 | $0 | 1 | $374,294 | $-374,294 |
| Crystal Adam | President, R&D | 0 | $0 | 12 | $6.99M | $-6.99M |
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and …
Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $0 and sold $7.69M worth of Tango Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.33M and sold $22.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.
| 2026-10-01 | Sale | Crystal Adam | President, R&D | 27,000 0.018% | $24.47 | $660,796 | -7.08% | |
| 2026-09-22 | Sale | Newcomb Jessica | Principal Accounting Officer | 8,200 0.0056% | $24.22 | $198,613 | -9.11% | |
| 2026-09-01 | Sale | Crystal Adam | President, R&D | 27,000 0.0166% | $22.37 | $603,909 | +4.21% | |
| 2026-08-03 | Sale | Crystal Adam | President, R&D | 27,000 0.0188% | $27.24 | $735,517 | -12.50% | |
| 2026-07-01 | Sale | Crystal Adam | President, R&D | 27,000 0.0223% | $29.59 | $798,908 | -14.27% | |
| 2026-06-01 | Sale | Crystal Adam | President, R&D | 27,000 0.023% | $22.87 | $617,571 | +9.46% | |
| 2026-05-01 | Sale | Crystal Adam | President, R&D | 27,000 0.0235% | $21.23 | $573,097 | +16.90% | |
| 2026-04-15 | Sale | Crystal Adam | President, R&D | 38,460 0.0327% | $25.00 | $961,500 | -2.01% | |
| 2026-04-01 | Sale | Crystal Adam | President, R&D | 27,000 0.0232% | $21.20 | $572,478 | +15.50% | |
| 2026-03-25 | Sale | Crystal Adam | President, R&D | 12,000 0.0099% | $20.11 | $241,320 | +17.03% | |
| 2026-03-05 | Sale | Crystal Adam | President, R&D | 20,251 0.0163% | $15.00 | $303,765 | +41.92% | |
| 2026-02-25 | Sale | Crystal Adam | President, R&D | 54,345 0.0498% | $12.77 | $694,208 | +87.65% | |
| 2026-02-03 | Sale | Weber Barbara | Director, Executive Chair | 30,519 0.027% | $12.26 | $374,294 | +86.22% | |
| 2026-02-03 | Sale | Crystal Adam | President, R&D | 18,452 0.0163% | $12.26 | $226,300 | +86.22% | |
| 2026-02-03 | Sale | Beckman Daniella | Chief Financial Officer | 10,317 0.0091% | $12.26 | $126,531 | +86.22% | |
| 2025-09-25 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 500,000 0.4619% | $8.02 | $4.01M | +146.55% | |
| 2025-09-16 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 363,541 0.313% | $7.04 | $2.56M | +154.15% | |
| 2025-09-08 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 86,459 0.0803% | $7.04 | $608,628 | +148.90% | |
| 2025-09-05 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 642,906 0.5828% | $7.00 | $4.5M | +142.51% | |
| 2025-08-22 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 302,194 0.2755% | $7.00 | $2.12M | +83.77% |
| Boxer Capital, LLC | 8198642 4.8625% | $189.96M | 3 | 1 | +19.37% | |
| Davis Aaron I. | director | 7123642 4.2249% | $165.05M | 3 | 0 | +36.79% |
| LEWIS JOSEPH | director | 7053642 4.1834% | $163.43M | 3 | 0 | +40.76% |
| BCTG Holdings, LLC | 10 percent owner | 4488450 2.662% | $104M | 1 | 1 | +7.42% |
| Rothenberg Mace | director | 31250 0.0185% | $724,062.50 | 2 | 0 | <0.0001% |
$11,583,737 | 45 | 49.75% | $4.66B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$151,136,640 | 31 | -1.41% | $3.95B | |
$5,066,938 | 27 | 26.38% | $3.7B |
| Increased Positions | 129 | +111.21% | 73M | +52.32% |
| Decreased Positions | 50 | -43.1% | 41M | -29.03% |
| New Positions | 55 | New | 21M | New |
| Sold Out Positions | 23 | Sold Out | 24M | Sold Out |
| Total Postitions | 195 | +68.1% | 173M | +23.29% |
| Trv Gp Iv, Llc | $123,805.00 | 10.27% | 13.86M | -3M | -17.77% | 2025-09-30 |
| Farallon Capital Management Llc | $96,060.00 | 7.97% | 10.76M | +2M | +17.47% | 2025-09-30 |
| Ecor1 Capital, Llc | $94,932.00 | 7.88% | 10.63M | 0 | 0% | 2025-09-30 |
| Boxer Capital Management, Llc | $87,259.00 | 7.24% | 9.77M | 0 | 0% | 2025-09-30 |
| Tcg Crossover Management, Llc | $76,228.00 | 6.32% | 8.54M | -2M | -20.49% | 2025-09-30 |
| Woodline Partners Lp | $53,847.00 | 4.47% | 6.03M | +22 | 0% | 2025-09-30 |
| Siren, L.L.C. | $52,537.00 | 4.36% | 5.88M | +3M | +74.84% | 2025-09-30 |
| Blackrock, Inc. | $50,427.00 | 4.18% | 5.65M | +183,653 | +3.36% | 2025-09-30 |
| Nextech Invest, Ltd. | $49,418.00 | 4.1% | 5.53M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $45,114.00 | 3.74% | 5.05M | +1M | +25.46% | 2025-09-30 |